Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Acquisitions & Divestments: 2022-2024

Historic Change in Acquisitions & Divestments for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $413.1 million.

  • Entrada Therapeutics' Change in Acquisitions & Divestments fell 9.36% to $75.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $330.6 million, marking a year-over-year decrease of 18.00%. This contributed to the annual value of $413.1 million for FY2024, which is 50.52% up from last year.
  • According to the latest figures from FY2024, Entrada Therapeutics' Change in Acquisitions & Divestments is $413.1 million, which was up 50.52% from $274.4 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Change in Acquisitions & Divestments ranged from a high of $413.1 million in FY2024 and a low of $76.2 million during FY2022.
  • For the 3-year period, Entrada Therapeutics' Change in Acquisitions & Divestments averaged around $254.6 million, with its median value being $274.4 million (2023).
  • Data for Entrada Therapeutics' Change in Acquisitions & Divestments shows a peak YoY soared of 260.07% (in 2023) over the last 5 years.
  • Entrada Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $76.2 million in 2022, then skyrocketed by 260.07% to $274.4 million in 2023, then soared by 50.52% to $413.1 million in 2024.